Mucommune

Executive Summary

Mucommune is a pre-clinical biotechnology company pioneering the 'muco-trapping' antibody platform, originating from research at Johns Hopkins and UNC Chapel Hill. The company focuses on engineering antibodies that specifically bind to and neutralize pathogens or inflammatory mediators within mucosal surfaces, offering a novel approach to treat inflammatory and autoimmune diseases. By leveraging its expertise in immunoengineering and drug delivery, Mucommune aims to develop microbiome-based therapeutics that modulate the host-microbiome interface to restore immune homeostasis. The company operates as a specialized R&D enterprise bridging academic innovation and clinical translation, with a lead program targeting inflammatory bowel disease (IBD) and other mucosal inflammatory conditions. While still in early stages, Mucommune's platform has the potential to address significant unmet needs in diseases where mucosal barrier dysfunction drives pathology.

Upcoming Catalysts (preview)

• Q4 2026Series A Financing to Advance Lead Program60% success
• Q1 2027Preclinical Proof-of-Concept Data in IBD Models70% success
• Q3 2026Academic Partnership or Licensing Deal for Muco-Trapping Technology50% success